The analysis of the novel intestinal hormone, IBCAP (Betagenin) in the pancreatic beta-cells functions.
Project/Area Number |
25461395
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Endocrinology
|
Research Institution | Saitama Medical University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
OKAZAKI YASUSHI 埼玉医科大学, 医学部, 教授 (80280733)
YOKOO TOMOTAKA 埼玉医科大学, 医学部, 助教 (80400688)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 糖尿病 / 消化管ホルモン |
Outline of Final Research Achievements |
We identified a gene of Betagenin = IBCAP as a novel intestinal hormone. Here, we synthesized a betagenin active peptide, and this peptide was found to stimulate DNA synthesis of the MIN6 cell in vitro. And this peptide injection alleviated diabetes in STZ treated diabetic mice. Our findings suggest betagenin as a potential therapeutic target for diabetes.
|
Report
(4 results)
Research Products
(9 results)